Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

Effekten av uppslukande virtuell verklighet och avkopplande videor på lungcancerpatienter

15 september 2026 uppdaterad av: Kadir Baysoy, Hacettepe University

Effekten av uppslukande virtuell verklighet och avkopplande videor på symptomens svårighetsgrad, nöd och livskvalitet hos patienter med lungcancer som genomgår kemoterapi

Lung cancer is one of the types of cancer with a high incidence and mortality rate in the world and in our country. Frequently used protocols in the chemotherapy treatment of lung cancer are the Platinum-based drugs. The main side effects of this chemotherapy protocols are nausea, vomiting, neutropenia and fatigue. The side effects of cancer and chemotherapy cause patients to experience distress and their quality of life is adversely affected. Some non-pharmacological methods such as meditation, breathing exercises, and massage can be used to manage the symptoms experienced by patients due to chemotherapy for supportive care. One of these methods is virtual reality. In addition, audio-visual (video) therapy methods are other methods that can be used in the symptom management of these patients. In this study, the effect of interactive/immersive virtual reality intervention and relaxant video intervention on symptom severity, distress level and quality of life of patients diagnosed with lung cancer will be evaluated. Patients will be assigned to 3 groups: virtual reality intervention group (VR), relaxant video application group (RV) and control group (CG) by stratified randomization according to the disease stage and drug type. During the chemotherapy treatment, the patients will take interactive/immersive virtual reality (VR group) or relaxant video application (RV group) consisting of nature-themed scenarios. The interventions will be done 2 times and about 20 minutes in the first day of each chemotherapy cycle, in total 2 cycles. The control group will receive routine nursing care. Research data will be collected at different intervals during the chemotherapy course with the Patient Information Form (only once), the Edmonton Symptom Assessment Scale, the NCCN Distress Thermometer, the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) and the Patient Follow-up Form and will be analyzed with the IBM SPSS program.

Studieöversikt

Detaljerad beskrivning

Lung cancer is one of the types of cancer with a high incidence and mortality rate in the world and in our country. Frequently used protocols in the chemotherapy treatment of lung cancer are the Platinum-based drugs. The main side effects of this chemotherapy protocols are nausea, vomiting, neutropenia and fatigue. The side effects of cancer and chemotherapy cause patients to experience distress and their quality of life is adversely affected. In addition to pharmacological approaches, some non-pharmacological methods such as meditation, breathing exercises, and massage can be used to manage the symptoms experienced by patients due to chemotherapy. One of these methods is the virtual reality application, which has started to be used in the field of health with the developing technology, allowing individuals to experience another reality where they are. In addition, audio-visual (video) therapy methods are other methods that can be used in the symptom management of these patients. It is stated that virtual reality intervention and audio-visual therapies (relaxant video application) have positive effects on cancer patients and patients receiving chemotherapy treatment. In this study, the effect of interactive/immersive virtual reality intervention and relaxant video application on symptom severity, distress level and quality of life of patients diagnosed with lung cancer will be evaluated. Patients diagnosed with lung cancer, receiving chemotherapy treatment for the first time, and whose protocols are Cisplatin+Etoposide, Carboplatin+Etoposide, Paclitaxel+Carboplatin, Docetaxel+Cisplatin, Cisplatin+Pemetrexed, Carboplatin+Pemetrexed, Cisplatin+Vinorelbine, Gemcitabine+Cisplatin/Carboplatin and only Cisplatin, will be included in the study. Patients will be assigned to 3 groups: virtual reality application group (VR), relaxant video application group (RV) and control group (CG) by stratified randomization according to the disease stage and drug type. During the chemotherapy treatment, an interactive/immersive virtual reality intervention (VR group) and relaxant video intervention (RV group) consisting of nature-themed scenarios, which are preferred due to their relaxing effects, will be carried out for 2 times, about 20 minutes, the first day of each chemotherapy cycle, during 2 chemotherapy cycles. The control group will receive routine/standard nursing care. Research data will be collected at different intervals during the chemotherapy cures with the Patient Information Form (only once), the Edmonton Symptom Assessment Scale, the NCCN Distress Thermometer, the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) and the Patient Follow-up Form and will be analyzed with the IBM SPSS program.

Studietyp

Interventionell

Inskrivning (Faktisk)

315

Fas

  • Inte tillämpbar

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studieorter

      • Ankara, Turkiet (Türkiye)
        • Ankara Etlik City Hospital
      • Ankara, Turkiet (Türkiye)
        • Ankara Bilkent City Hospital
      • Ankara, Turkiet (Türkiye)
        • Hacettepe University Oncology Hospital

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

18 år och äldre (Vuxen, Äldre vuxen)

Tar emot friska volontärer

Nej

Kön som är behöriga för studier

Allt

Beskrivning

Inclusion Criteria:

  • are over 18 years old,
  • diagnosed with lung cancer,
  • will receive chemotherapy for the first time,
  • will receive at least 2 cycles of chemotherapy treatment
  • agree to participate in the study
  • ECOG performance status of 2 or less

Exclusion Criteria:

  • Having a cognitive and psychiatric disorder and diagnosis,
  • Having brain metastasis or chronic disease related to the head-brain region,
  • Having vision-hearing problems,
  • Having epilepsy, vertigo, chronic severe headache, dizziness problems,
  • Having a history of virtual reality, simulator or motion sickness,
  • Having/declaring that he/she has open area, underwater, specific animal phobia,
  • Do not agree to participate in the study

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Primärt syfte: Stödjande vård
  • Tilldelning: Randomiserad
  • Interventionsmodell: Parallellt uppdrag
  • Maskning: Ingen (Open Label)

Vapen och interventioner

Deltagargrupp / Arm
Intervention / Behandling
Experimentell: Virtual Reality Group

Immersive Virtual Reality Group: Immersive virtual reality will be applied to this group 2 times during chemotherapy infusion (total of 2 chemotherapy cures) to reduce the symptom severity and distress level and improve the quality of life.

For Immersive Virtual Reality interventions; The Meta Quest 2 device will be used and the virtual scenarios/contents were selected from "Nature Treks" app bought by the researcher.

(Initially, a total of 6 VR contents and 6 similar videos were created for patients who received cisplatin+etoposide treatment consisting of three sessions of one chemotherapy cure (4 cure, 12 sessions). Due to the limited number of patients and regular attendance to treatment, other similar drug treatments were also included and finally, a total of 2 cures, 2 VR contents and 2 videos were selected and these 2 contents will be used.)

These:

  1. Walking in the Forest and Similar Video
  2. Sitting on the Beach and Similar Video

To apply immersive virtual reality (Virtual Environments)

Experimentell: Relaxing Video Group

Relaxing Video Group: Participants in this group will watch relaxing videos 2 times for 20 min during chemotherapy infusion (total of 2 chemotherapy cures) to reduce the symptom severity and distress level and improve the quality of life.

The videos are slideshow-type videos consisting of various images and relaxing music prepared by the researcher. The videos were created by selecting images/sounds similar with the themes/scenarios in the virtual reality application.

(Initially, a total of 6 VR contents and 6 similar videos were created for patients who received cisplatin+etoposide treatment consisting of three sessions of one chemotherapy cure (4 cure,12 sessions). Due to the limited number of patients and regular attendance to treatment, other similar drug treatments were also included and finally, a total of 2 cures, 2 VR contents and 2 videos were selected and these 2 contents will be used)These:Walking in the Forest and Similar Video,Sitting on the Beach and Similar Video

To watch relaxing videos including pictures and sounds prepared by researcher

Inget ingripande: Control Group

Patients in the control group will receive standard nursing care applied in the chemotherapy unit. Standard nursing care; Training patients on the method of chemotherapy administration, its duration, content, side effects, and coping, preparing the drugs for administration, preparing the patients for treatment, starting the infusion, monitoring the patients during the infusion for side effects, infusion complications, changes in vital signs, etc. Includes applications.

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Edmonton Symptom Assessment Scale (ESAS)
Tidsram: Immediately before (T1, T3) and immediately after (T2, T4) each 20-minute intervention session across the first two chemotherapy cycles; same time points in the control group. 4 assessments in total.

Changes on overall score of Edmonton Symptom Assessment Scale.

The scale is a numerical scale between 0 and 10 developed to measure each symptom level (total 12 symptoms). Lower scores indicate lower symptom levels.

Immediately before (T1, T3) and immediately after (T2, T4) each 20-minute intervention session across the first two chemotherapy cycles; same time points in the control group. 4 assessments in total.

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
National Comprehensive Cancer Network Distress Thermometer (NCCN-DT)
Tidsram: Immediately before (T1, T3) and immediately after (T2, T4) each 20-minute intervention session across the first two chemotherapy cycles; same time points in the control group. 4 assessments in total.

Changes on overall score of Distress Scale.

The scale is a numerical scale between 0 and 10 developed to measure stress levels. Lower scores indicate lower stress levels.

Immediately before (T1, T3) and immediately after (T2, T4) each 20-minute intervention session across the first two chemotherapy cycles; same time points in the control group. 4 assessments in total.
The European Organization for Research and Treatment of Cancer Core Quality of Life Questionnaire (EORTC QLQ-C30)
Tidsram: Before the first intervention session (T1) in the first chemotherapy cycle and after the final intervention session (T4) in the second cycle; same time points in the control group. 2 assessments in total.

Changes on overall score of Quality of Life Scale.

The scale is a multi-dimension scale including total 30 questions to measure quality of life level. Minimum score is 0, and maximum score is 100.

Before the first intervention session (T1) in the first chemotherapy cycle and after the final intervention session (T4) in the second cycle; same time points in the control group. 2 assessments in total.

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Publikationer och användbara länkar

Den som ansvarar för att lägga in information om studien tillhandahåller frivilligt dessa publikationer. Dessa kan handla om allt som har med studien att göra.

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Faktisk)

15 januari 2025

Primärt slutförande (Faktisk)

30 september 2025

Avslutad studie (Faktisk)

30 september 2025

Studieregistreringsdatum

Först inskickad

27 november 2024

Först inskickad som uppfyllde QC-kriterierna

6 mars 2025

Första postat (Faktisk)

7 mars 2025

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

18 september 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

15 september 2026

Senast verifierad

1 september 2026

Mer information

Termer relaterade till denna studie

Andra studie-ID-nummer

  • KA-22070 (Hacettepe Un.)
  • 21-AKD-31 (Registeridentifierare: Republic of Turkey Ministry of Health Turkish Medicines and Medical Devices Agency (TİTCK))

Plan för individuella deltagardata (IPD)

Planerar du att dela individuella deltagardata (IPD)?

NEJ

IPD-planbeskrivning

It will be shared after the article published

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Nej

Studerar en amerikansk FDA-reglerad produktprodukt

Nej

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera